General Information of This Drug (ID: DMEXW31)

Drug Name
NSC-663284   DMEXW31
Synonyms
NSC 663284; 383907-43-5; NSC-663284; NSC663284; CDC25 Phosphatase Inhibitor II, NSC 663284; 6-Chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione; 6-chloro-7-{[2-(morpholin-4-yl)ethyl]amino}quinoline-5,8-dione; DA3003-1; 6-Chloro-7-((2-morpholinoethyl)amino)quinoline-5,8-dione; AC1Q3HBF; AC1Q3HBE; SPS8I1; MLS006010693; SCHEMBL2556224; AC1L8E02; CTK4H9880; CHEBI:92053; DTXSID50327512; MolPort-003-983-788; HMS3268K22; BCP16027; MFCD08276924; BS0130; ZINC100002044; AKOS024456823; CS-7519; NCGC00092289-01; NCGC00092289-02
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
NSC-663284 + Ruxolitinib DC1X5IA Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [2]
------------------------------------------------------------------------------------

References

1 Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5.
2 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.